Risk of cancer in a large cohort of nonaspirin NSAID users: A population-based study

British Journal of Cancer

Volumn 88, Issue 11, 2003, Pages 1687-1692

  Sorensen H T ^a,b,g   Friis, S ^c   Norgard B ^a   Mellemkjaer L ^c   Blot, W J ^b,d   McLaughlin, J K ^b,d   Ekbom, A ^e   Baron, J A ^f  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^d INTERNATIONAL EPIDEMIOLOGY INSTITUTE   (United States)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f DARTMOUTH MEDICAL SCHOOL   (United States)

^g Building 260 ^*  (Denmark)

Author keywords

Epidemiology; NSAIDs; Prevention; Risk

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER REGISTRY; CANCER RISK; COHORT ANALYSIS; COLORECTAL CARCINOMA; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA BASE; DISEASE ASSOCIATION; FEMALE; HUMAN; KIDNEY CANCER; LUNG CANCER; MALE; OVARY CANCER; POPULATION; PRIORITY JOURNAL; RECTUM CARCINOMA; REDUCTION; STANDARDIZATION; STOMACH CANCER;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COHORT STUDIES; COLORECTAL NEOPLASMS; DENMARK; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; OVARIAN NEOPLASMS; POPULATION SURVEILLANCE; REGISTRIES; RISK FACTORS; STOMACH NEOPLASMS;

EID: 0038605671     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600945     Document Type: Article

References (45)

1. Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, Kato I, Koenig KL, Shore RE (2001) Aspirin and epithelial ovarian cancer. Prev Med 33: 682-687
2. Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, Koenig KL, Shore RE (2002) Aspirin and lung cancer in women. Br J Cancer 87: 49-53
3. Baron JA, Sandler RS (2000) Nonsteroidal anti-inflammatory drugs and cancer prevention. Annu Rev Med 51: 511-523
4. Coogan PF, Rosenberg L, Louik C, Zauber AG, Stolley PD, Strom BL, Shapiro S (2000) NSAIDs and risk of colorectal cancer according to presence or absence of family history of the disease. Cancer Causes Control 11: 249-255
5. Cramer DW, Harlow BL, Titus-Ernstoff L, Bohlke K, Welch WR, Greenberg ER (1998) Over-the-counter analgesics and risk of ovarian cancer. Lancet 351: 104-107
6. DuBois R, Smalley W (1996) Cyclooxygenase, NSAIDs and colorectal cancer. J Gastroenterol 31: 898-906
7. Egan KM, Stampfer MJ, Giovannucci E, Rosner BA, Colditz GA (1996) Prospective study of regular aspirin use and the risk of breast cancer. J Natl Cancer Inst 88: 988-993
8. Farrow DC, Vaughan TL, Hansten PD, Stanford JL, Risch HA, Gammon MD, Chow WH, Dubrow R, Mayne ST, Schoenberg JB, West AB, Rotterdam H, Fraumeni JF Jr, Blot WJ. (1998) Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 7: 97-102
9. Friis S, Sørensen HT, McLaughlin JK, Johnsen SP, Blot WJ, Olsen JH (2003) population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer 88: 684-688
10. Funkhouser EM, Sharp GB (1995) Aspirin and reduced risk of esophageal carcinoma. Cancer 76: 1116-1119
11. Gaist D, Sørensen HT, Hallas J (1997) The Danish Prescription Registries. Dan Med Bull 44: 445-448
12. Garidou A, Tzonou A, Lipworth L, Signorello LB, Kalapothaki V, Trichopoulos D (1996) Life-style factors and medical conditions in relation to esophageal cancer by histologic type in a low-risk population. Int J Cancer 68: 295-299
13. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, Speizer FE (1995) Aspirin and the risk of colorectal cancer in women. N Engl J Med 333: 609-614
14. Greenberg ER, Baron JA, Freeman Jr DH, Mandel JS, Haile R (1993) Reduced risk of large-bowel adenomas among aspirin users The Polyp Prevention Study Group. J Natl Cancer Inst 85: 912-916
15. Harris RE, Kasbari S, Farrar WB (1999) Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer. Oncol Rep 6: 71-73
16. Harris RE, Namboodiri KK, Farrar WD (1996) Non-steroidal anti-inflammatory drugs and breast cancer. Epidemiology 7: 203-205
17. Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ, Tarnawski AS (1999) Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 5: 1418-1423
18. Kawamori T, Rao CV, Seibert K, Reddy BS (1998) Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 58: 409-412
19. Kulkarni S, Rader JS, Zhang F, Liapis H, Koki AT, Masferrer JL, Subbaramaiah K, Dannenberg AJ (2001) Cyclooxygenase-2 is over-expressed in human cervical cancer. Clin Cancer Res 7: 429-434
20. Kune GA, Kune S, Watson LF (1988) Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 48: 4399-4404
21. Langman MJ, Cheng KK, Gilman EA, Lancashire RJ (2000) Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 320: 1642-1646
22. McLaughhn JK, Lipworth L (2000) Epidemiologic aspects of renal cell cancer. Semin Oncol 27: 115-123
23. Meier CR, Schmitz S, Jick H (2002) Association between acetaminophen or nonsteroidal antiinflammatory drugs and risk of developing ovarian, breast, or colon cancer. Pharmacotherapy 22: 303-309
24. Mellemkjær L, Blot WJ, Sørensen HT, Thomassen JK, McLaughlin JK, Nielsen GL, Olsen JH (2002) Upper gastrointestinal bleeding among users of NSAIDs: a population-based cohort study in Denmark. Br J Clin Pharmacol 53: 173-181
25. Morris CD, Armstrong GR, Bigley G, Green H, Attwood SEA (2001) Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 96: 990-996
26. Moysich KB, Mettlin C, Piver MS, Natarajan N, Menezes RJ, Swede H (2001) Regular use of analgesic drugs and ovarian cancer risk. Cancer Epidemiol Biomarkers Prev 10: 903-910
27. Muscat JE, Stellman SD, Wynder EL (1994) Nonsteroidal antiinflammatory drugs and colorectal cancer. Cancer 74: 1847-1854
28. Paganini-Hill A, Chao A, Ross RK, Henderson BE (1989) Aspirin use and chronic disease: a cohort study of the elderly. BMJ 299: 1247-1250
29. Peleg II, Maibach HT, Brown SH, Wilcox CM (1994) Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med 154: 394-399
30. Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, Warlow C, Hafner B, Thompson E, Norton S (1988) Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 296: 313-316
31. Roberts RO, Jacobson DJ, Girman CJ, Rhodes T, Lieber MM, Jacobsen SJ (2002) A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin Proc 77: 219-225
32. Rodrigues LAG, Huerta-Alvarez C (2001) Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Epidemiology 12: 88-93
33. Rosenberg L (1995) Nonsteroidal anti-inflammatory drugs and cancer. Prev Med 24: 107-109
34. Rosenberg L, Louik C, Shapiro S (1998) Nonsteroidal antiinflammatory drug use and reduced risk of large bowel carcinoma. Cancer 82: 2326-2333
35. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, StoHey PD, Shapiro S (1991) A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 83: 355-358
36. Sales KJ, Katz AA, Davis M, Hinz S, Soeters RP, Hofmeyr MD, Millar RP, Jabbour HN (2001) Cyclooxygenase-2 expression and prostaglandin E(2) synthesis are up-regulated in carcinomas of the cervix: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. J Clin Endocrinol Metab 86: 2243-2249
37. Sales KJ, Katz AA, Howard B, Soeters RP, Millar RP, Jabbour HN, Soeters RP (2002) Clooxygenase-1 is up-regulated in cervical carcinomas: autocrine/paracrine regulation of cyclooxygenase-2, prostaglandine receptors, and angiogenic factors by clooxygenase-1. Cancer Res 62: 424-432
38. Sandler RS, Galanko JC, Murray SC, Helm JF, Woosley JT (1998) Aspirin and nonsteroidal antiinflammatory agents and risk for colorectal adenomas. Gastroenterology 114: 441-447
39. Schreinemachers DM, Everson RB (1994) Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5: 138-146
40. Smalley W, Ray WA, Daugherty J, Griffin MR (1999) Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. Arch Intern Med 159: 161-166
41. Storm HH, Michelsen EV, Clemmensen IH, Pihl J (1997) The Danish Cancer Registry-history, content, quality and use. Dan Med Bull 44: 549-553
42. Suh O, Mettlin C, Petrelli NJ (1993) Aspirin use, cancer, and polyps of the large bowel. Cancer 72: 1171-1177
43. Sørensen HT, Olsen JH, Mellemkjær L, Thulstup AM, Steffensen FH, McLaughlin JK, Baron JA (2000) Cancer risk and mortality in users of calcium channel blockers. A cohort study. Cancer 89: 165-170
44. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath Jr CW (1993) Aspirin use and risk of fatal cancer. Cancer Res 53: 1322-1327
45. Thun MJ, Namboodiri MM, Heath Jr CW (1991) Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325: 1593-1596